Endocrine - Parathyroid disease Flashcards
Physiological effects of PTH
Source of PTH
↑Ca ↓PO4 ↑ALP
- Increase Ca resorption from bone via osteoblasts and osteoclasts
- Increase reabsorption of Ca from DCT in kidneys, Decrease Phosphate reabsorption
- Increase intestinal uptake of Ca via formation of 1,25-dihydroxyvitamin D
Source: parathyroid chief cells
Physiological effects of Vitamin D
Sources of Vit D
Processing
↑Ca ↑PO4 ↑ALP
- Increase Ca uptake in intestine by increase Calcium Binding Protein
- Increase Calcium resorption from bone in high dose
- Increase Phosphate uptake in intestine
Processing: vitamin D3 or D2
→ 25-hydroxylation in liver → calcidiol (25-(OH)-D3)
→ 1-hydroxylation in kidney → calcitriol (1,25-(OH)2-D3)
Source:
→ Dietary: D3 from animal, D2 from plants
→ Sunlight: D3
Physiological effects of Calcitonin
Source of Calcitonin
↓Ca ↓PO4
(physiologically negligible to Ca homeostasis as thyroidectomy does NOT affect serum Ca)
- Decrease Osteoclast-mediated bone resorption
- Decrease reabsorption of Ca from DCT in Kidney, Increase Phosphate excretion
Source: thyroid parafollicular C cells
List all physiological factors that modulate serum Ca level
PTH
Calcitonin
Vitamin D
Albumin: Alb-bound Ca amounts to 40% of plasma Ca
Phosphate level (affect ionic calcium balance, can precipitate Ca out of serum)
Serum pH level (affect ionic calcium level, H+ ions compete with Ca2+ ions for binding sites on albumin)
Corrected Calcium
- Indications
- Formula
Indication: Any condition with hypoalbuminaemia (most Ca bind to albumin, remainder bind to globulin)
Total Calcium may be low but Ionized Calcium is normal
- Nephrotic syndrome
- Liver cirrhosis
- Malnutrition
- Protein-losing enteropathy
- Acute or chronic inflammation (negative phase reactant)
- Absorptive problem: e.g. IBS, Bowel cancer…etc
Formula = Total Ca (mmol/L) + [0.02 x (40 - albumin in g/L)]
Albumin-corrected Ca =
For each ↓1g/L in Alb below 40g/L, Ca should be adjusted ↑0.02mmol/L (provided that Alb is between 20-51).
Role of albumin in blood
- regulation of colloid osmotic pressure or protein concentration within the blood plasma
- transport of free fatty acids and other molecules to the liver (unconjugated bilirubin, metals, ions) for storage or utilization
- binding of drugs and alteration of pharmacokinetics (half-life, biological activity levels, metabolism)
- buffering plasma pH
- scavenging reactive oxygen species to avoid inflammation and associated damage
- functioning as a reservoir of nitric oxide for the regulation of blood pressure
- prevention of coagulation and platelet aggregation in an action similar to the commonly used anticoagulant heparin
- inhibits inflammatory mediators such as TNF-α and complement 5a (C5a) to reduce the overall inflammatory response
Causes of Hypercalcemia
- Hyperparathyroidism (Primary or tertiary)
- Hypercalcemia of Malignancy
- Excessive vitamin D or Calcium (Vit. D intoxication, Milk alkali syndrome)
- Granulomatous disease - Increase sensitivity to Vitamin D (e.g. Tuberculosis, Sarcoidosis)
- Hypocalciuric Hypercalcemia (Thiazide diuretics, Familial mutation of Calcium sensing receptor CaSR)
- Adrenal insufficiency
- Hyperthyroidism
Pathophysiology of adrenal insufficiency causing Hypercalcemia
Hypovolaemia > Reduced GFR > Reduced calcium filtration > Increase Calcium renal reabsorption
Increase 1-alpha- hydroxylase activity > Increase intestinal absorption of Calcium
Outline the flowchart for approaching hypercalcaemia
S/S hypercalacaemia
Mostly asymptomatic
□ Non-specific: fatigue, depression, drowsiness, malaise
□ Specific: usually clinically a/w dehydration
→ Stones: nephrocalcinosis, renal stones (if long-standing)
→ Bones: bone pain, osteoporosis (if hyperPTH)
→ Moans: constipation, anorexia, abdominal pain, PUD, pancreatitis
→ Thrones: polyuria, dehydration, polydipsia
→ Psychic overtones: confusion, depression, anxiety, hallucination
□ Others: band keratopathy, short QTc, distal RTA
Outline mild, moderate and severe hypercalcaemia levels
Mild:
Serum Ca < 3 mmol/L
Moderate:
Serum Ca 3.0 - 3.5 mmol/L
Severe:
Serum Ca > 3.5 mmol/L
Management of mild symptomatic hypercalcaemia
- Avoid aggravating factors
- Maintain hydration
- Avoid high calcium diet (>1000mg/day)
Management of moderate/ severe hypercalcaemia
- Rapid control of Ca level
- Early Dx of underlying cause
Medical options:
- Fluid replacement with Saline +/- Loop diuretics
- IV bisphosphonate (Zoledronic acid or Pamidronate)
- Calcitonin (subcutaneous)
- Glucocorticoids (Prednisolone)
- Monoclonal antibodies against RANKL
- Dialysis
Fluid replacement for HyperCa
MoA, Monitoring
MoA:
- Infuse normal saline > inhibition of sodium reabsorption in PCT and Loop of Henle > Excretion of Calcium
Monitoring:
- Infusion rate depends on age, comorbid conditions (HF, CKD…etc)
- Monitor electrolytes and fluid balance
- Add Loop diuretics (Frusemide) if develop edema after rehydration
IV bisphosphonate for hyperCa
MoA
Indication
Time course
S/EE
MoA:
Inorganic pyrophosphate analog absored to surface of bone hydroxyapatite > Interfere with osteoclast-mediated bone resorption > Decrease Ca release from bone
Indication: Moderate to severe HyperCa
Time course: 1-2 days to take effect, 2-4 days for maximum effect
S/E: Osteonecrosis of jaw, Atypical fracture, Flu-like symptoms, renal impairment
Calcitonin for HyperCa
MoA
Time course
S/E
MoA: Increase renal Ca excretion and decrease bone resorption
Time course: Rapid onset, give subcutaneously every 12 hours (Salmon Calcitonin)
S/E: Nausea, Hypersensitivity reaction, Tachyphylaxis
Glucocorticoids for HyperCa
MoA
Indication
MoA: Decrease Calcitriol production by activated mononuclear cells
Indications:
- Excessive ingestion or admin. of Vitamin D
- Endogenous overproduction of calcitriol - Granulomatous diseases, lymphoma…etc
Monoclonal Ab against RANKL for HyperCA
MoA
Indication
Precaution
MoA:
Block the action of RANK Ligand released by Osteoblasts that increase formation, activity and survival of osteoclasts
Decrease bone resorption and Ca release
Indication:
Refractory Tx to IV bisphosphonate
Contraindicated for IV bisphosphonate due to renal failure (Denosumab not excreted through kidneys)
Persistent HyperCa due to malignancy
Precaution: Vitamin D depletion before admin.
Dialysis for HyperCa
Indication
Very severe HyperCa (Serum Ca > 4.5 mmol/L)
Refractory severe hyperCa complicated by renal failure (renders other therapy ineffective/ contraindicated)
Most common cause of hypercalcaemia
Epidemiology
Subtypes
Primary hyperparathyroidism
Epidemiology:
- 6th-7th decade
- F:M - 2-3:1
- 1-2/1000
Types:
- Solitary parathyroid adenoma (85%)
- Parathyroid hyperplasia (10-15%)
- Double adenoma (1-2%)
- Parathyroid carcinoma (1%)
Symptoms of severe hyperCa
Constitutional: Weakness, tiredness, anorexia
GIT: Nausea, vomiting, constipation
Nephrogenic DI: Thirst, dry mouth, polyuria
Neural: Mental confusion and drowsiness
Complications of severe hyperCa
Renal:
Renal stone, nephrocalcinosis, hypertension, renal failure
Bone:
Osteoporosis, bone pain, fracture, Parathyroid bone disease
Gastrointestinal:
Epigastric pain, dyspepsia
MSS:
Calcification of cartilage, joint pain
Endocrine: Multiple endocrine neoplasia (MEN1, MEN2)
Pharmacological effect of PTH on bones
Intermitted low dose (Teriparatide) - Anabolic action with increase BMD (indicated Osteoporosis)
Continuous high dose - Bone resorption (esp. cortical bone more than trabecular bone)
Features of parathyroid bone disease
Cystic osteitis fibrosa and osteopenia
Bone pain, subperiosteal resorption (esp. at phalanges)
Bone deformity: Bone cysts (esp. at central medullary parts of MCP, ribs and pelvis)
Osteoclastoma or Brown Tumors (esp. at trabecular portions of jaw, long bones and ribs)
Pathological fractures
Skull ‘salt and pepper’ appearance